Through our network of global connections, we aim to make knowledge not just available, but valuable. We want to help you acquire expertise that can be directly applied to your practice. Explore the various medical education resources below:
EHA CAR-T Program
An 8-course program covering all aspects of CAR-T; mechanisms of action, the process of CAR-T manufacture and infusion, treatment of hematopoietic malignancies and patient selection, CRS, and other complications as well as ethics and consent, multidisciplinary care and regulatory aspects.
Lymphodepletion optimization for CAR T-cell therapy
At the 8th annual meeting of the Society of Hematologic Oncology (SOHO), Elizabeth Budde presented how the process of lymphodepletion can be optimized to aid persistence and efficacy of infused CAR T-cells.
2nd European CAR T Cell Meeting (Jan 30 - Feb 1, 2020) Report
Sections: (1) The clinical landscape for CAR-T, and current developments in Europe, (2) The global efforts to improve CAR T-cell therapy and (3) Regulatory considerations and directions for the European CAR-T landscape
Is there an optimal time to deploy immunotherapies in multiple myeloma?
During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Meral Beksaç, Ankara University School of Medicine, Ankara, TR, about immunotherapy for MM: Is there an optimal time to deploy immunotherapies in multiple myeloma?
How I treat relapsed acute lymphoblastic leukemia in the pediatric population
Immunotherapy changed the therapeutic landscape of children with relapsed ALL. Several cases highlighting contemporary treatment decision-making are presented in this educational paper.
EHA CAR-T Course: Processes in CAR-T
"Processes in CAR-T" - the third CAR-T course within EHA's new immunotherapy program is now freely accessible via the EHA Campus. This course addresses processes involved in the manufacture of CAR T-cells from apheresis to treatment, as well as the role of different team members including pharmacists and nurses. It also includes considerations specific to pediatric patients.
ERIC 2020 | Developing T-cell based therapies for CLL treatment
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, discusses T-cell based therapy to treat chronic lymphocytic leukemia (CLL).
IACH Focus on Leukemia 2020 | Antibody-based therapy to treat AML: radioimmunoco...
Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of antibody-based therapy in acute myeloid leukemia (AML).
Exploring the Future of CAR T-Cell Therapy in Multiple Myeloma
C. Ola Landgren, MD, PhD, chief of Myeloma Service and hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses what is next for chimeric antigen receptor (CAR) T-cell therapy in the multiple myeloma landscape.
Cancer immunotherapy update
Because cancer treatment (surgery, radiation, and chemotherapy) frequently fails, researchers began asking why patients’ immune systems don’t respond to cancer cells like they do to bacteria and viruses.